Why the study?
Does the use of intracoronary vasodilators provide a benefit in patients with ST segment elevation myocardial infarction?
Does the use of intracoronary vasodilators provide a benefit in patients with ST segment elevation myocardial infarction?
Answers are grounded in this paper and cite their sources.
This editorial introduces a discussion on a Cochrane Review evaluating the efficacy of intracoronary vasodilators for managing reperfusion injury and the no-reflow phenomenon in STEMI patients.
This is the first edition of our new section ‘Cochrane Corner’, in which we will discuss important Cochrane Reviews (systematic reviews) of potential interest for the readers of Heart . These reviews are often very extensive and can be difficult to read; we aim to present them in a condensed way and will also discuss the clinical implications of the results. The core information will be presented in a short PICO format (population–intervention–control treatment–outcome). The outcomes for ST segment elevation myocardial infarctions has improved dramatically with primary percutaneous coronary intervention (PPCI) and an increasing number of hospitals offering this service.1 This has improved call-to-balloon times and outcomes. However, having achieved much faster and efficient reperfusion, we are now confronted with an unresolved issue, reperfusion injury and the no-/slow reflow phenomenon. The no-reflow phenomenon is defined as …
No takes yet. Share an insight, caveat, or question.
Meier et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: